Needham Maintains Buy on Mereo BioPharma Group, Raises Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum maintains a Buy rating on Mereo BioPharma Group (NASDAQ:MREO) and raises the price target from $6 to $7.
June 12, 2024 | 10:37 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Gil Blum has maintained a Buy rating on Mereo BioPharma Group and increased the price target from $6 to $7, indicating confidence in the company's future performance.
The raised price target and maintained Buy rating from a reputable analyst suggest positive sentiment and potential upside for Mereo BioPharma Group's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100